SPPI News and Press, Spectrum Pharmaceuticals Inc. From 09/23/22

-- Multiple tranche debt financing provides Spectrum with up to $65 million -- -- Funding provides additional capital to optimize commercial launch of ROLVEDON™ -- -- Cash runway extended through 2024 -- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SP...

Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Ad...

An independent group of experts voted against the approval of lung cancer drug poziotinib developed by clinical-stage biotech Spectrum Pharmaceuticals ( NASDAQ: SPPI ) on Thursday, clouding its path for FDA approval. With a PDUFA date on Nov. 24, the tyrosine kinase inhibi...

H.C. Wainwright lowered the price target on the clinical-stage biotech Spectrum Pharmaceuticals ( NASDAQ: SPPI ) Wednesday, noting that the FDA staff documents on its lung cancer drug poziotinib suggested a more “argumentative” AdCom meeting ahead. SPPI shares ...

US FDA scientists are concerned about the data Spectrum Pharmaceuticals ( NASDAQ: SPPI ) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday . Shares are down 28% in Tuesday morning trading. ...

Summary Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve the quality of life of patients suffering from various types of cancer. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology firm Spectrum Pharmaceuticals (NASDAQ: SPPI ) recently received regulatory approval for its inflation-reducing injections associated with anti-cancer drugs, thus driving SPPI stock significantly higher o...

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI). On August 6, 2021, the Company dis...

Whether you’re a seasoned trader making money with penny stocks or just getting your feet wet, 2022 has been a wild year for all levels of experience. This week, particularly, marks somewhat of the calm before the storm as September is likely to heat up even more. Stock Market Go...